A practical reference on animal model: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-26 and is reviewed periodically as new material appears.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Neuromodulation is "the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body". It is carried out to normalize – or modulate – nervous tissue function. Neuromodulation is an evolving therapy that can involve a range of electromagnetic stimuli, such as a magnetic field (rTMS), an electric current, or a drug delivered directly into the subdural space (intrathecal drug delivery). Emerging applications involve targeted introduction of genes or gene regulators and light (optogenetics), and by 2014, these had been at minimum demonstrated in mammalian models, or first-in-human data had been acquired. The most clinical experience has been with electrical stimulation. Neurotherapy, in modern use, is a synonym for neuromodulation. While neurotherapy may have a broader meaning, its modern definition focuses exclusively on technological methods that exert an energy-based effect on the development of a balanced nervous system in order to address symptom control and cure several conditions. Neurotherapy is a medical treatment that implements systemic targeted delivery of an energy stimulus or chemical agents to a specific neurological zone in the body to alter neuronal activity and stimulate neuroplasticity in a way that develops (or balances) a nervous system in order to treat different diseases, restore and/or to improve patients' physical strength, cognitive functions, and overall health.
Amin al-Husayni, president – member of the al-Husayni clan, the Grand Mufti of Jerusalem, and president of the Supreme Muslim Council until his dismissal from that position Raghib al-Nashashibi – member of the Nashashibi clan, which was considered to be political rivals of the al-Husayni clan, and to hold moderate views when compared to the more militant views of the al-Husayni, member of the National Defence Party Jamal al-Husayni – related to Amin al-Husayni and chairman of the Palestine Arab Party, member of the Supreme Muslim Council Yaqub al-Ghusayn – member and representative of the Youth Congress Party, member of the Supreme Muslim Council, deported Abd al-Latif Salah – founder of the National Bloc Husayin al-Khalidi – founder and representative of the Reform Party, deported Awni Abd al-Hadi – leader of the Istiqlal (Independence) Party, who was appointed General Secretary Ahmed Hilmi Pasha – treasurer, deported. Initially, the committee included representatives of the rival Nashashibi and al-Husayni clans. The committee was formed after the 19 April call for a general strike of Arab workers and businesses, which marked the start of the 1936–39 Arab revolt. On 15 May 1936, the committee endorsed the general strike, calling for an end to Jewish immigration; the prohibition of the transfer of Arab land to Jews; and the establishment of a National Government responsible to a representative council. Later it called for the nonpayment of taxes. Raghib al-Nashashibi, of the Nashashibi clan and member of the National Defence Party soon withdrew from the committee.
Sweating allows the body to regulate its temperature. Sweating is controlled from a center in the preoptic and anterior regions of the brain's hypothalamus, where thermosensitive neurons are located. The heat-regulatory function of the hypothalamus is also affected by inputs from temperature receptors in the skin. High skin temperature reduces the hypothalamic set point for sweating and increases the gain of the hypothalamic feedback system in response to variations in core temperature. Overall, however, the sweating response to a rise in hypothalamic ('core') temperature is much larger than the response to the same increase in average skin temperature. Sweating causes a decrease in core temperature through evaporative cooling at the skin surface. As high energy molecules evaporate from the skin, releasing energy absorbed from the body, the skin and superficial vessels decrease in temperature. Cooled venous blood then returns to the body's core and counteracts rising core temperatures. There are two situations in which the nerves will stimulate the sweat glands, causing perspiration: during physical heat and during emotional stress. In general, emotionally induced sweating is restricted to palms, soles, armpits, and sometimes the forehead, while physical heat-induced sweating occurs throughout the body. Human sweat is not pure water; though it contains no protein, it always contains a small amount (0.2–1%) of solute. When a person moves from a cold climate to a hot climate, adaptive changes occur in the sweating mechanisms of the person.
Males and females are affected equally. The disease was discovered in 1934 by Ivar Asbjørn Følling, with the importance of diet determined in 1935. As of 2023, genetic therapies that aim to directly restore liver PAH activity are a promising and active research field.
Sources: en.wikipedia.org
=== Initial concerns and industry response === In 1997, in response to mounting concern over the serious side effects of ephedra, the FDA proposed a ban on products containing 8 mg or more of ephedrine alkaloids and stricter labeling of low-dose ephedra supplements. The FDA also proposed that ephedra labels be required to disclose the health risks of ephedra, such as heart attack, stroke, and death. In response, the supplement industry created a public relations group, the Ephedra Education Council, to oppose the changes, and commissioned a scientific review by a private consulting firm, which reported that Ephedra was safe. The Ephedra Education Council also attempted to block the publication of a study confirming wide discrepancies between the labeled potency of supplements and the actual amount of ephedra in the product. Metabolife, makers of the best-selling brand of ephedra supplement, had received over 14,000 complaints of adverse events associated with its product. These reports were not initially provided to the FDA. Co-founder of Metabolife, Michael Ellis, was sentenced in 2008 to six months in federal prison for his failure to report adverse effects from his company's products to the FDA. Senators Orrin Hatch (R. Utah) and Tom Harkin (D. Iowa), authors of the Dietary Supplements Health and Education Act, questioned the scientific basis for the FDA's proposed labeling changes and suggested that the number of problems reported were insufficient to warrant regulatory action.
cytidine (C, Cyd) One of the four standard nucleosides used in RNA molecules, consisting of a cytosine base with its N9 nitrogen bonded to the C1 carbon of a ribose sugar. Cytosine bonded to deoxyribose is known as deoxycytidine, which is the version used in DNA.
=== In cellular biology === It is also used in cellular biology as an inhibitor of the lipid raft-caveolae endocytosis pathway on mammalian cells, at concentrations around 3 μg/ml. Nystatin is also used as a tool by scientists performing "perforated" patch-clamp electrophysiological recordings of cells. When loaded in the recording pipette, it allows for measurement of electrical currents without washing out the intracellular contents, because it forms pores in the cell membrane that are permeable to only monovalent ions, preferably cations such as sodium, potassium, lithium, and cesium.
Sources: en.wikipedia.org
Lindow Man, also known as Lindow II and (in jest) as Pete Marsh, is the preserved bog body of a man discovered in a peat bog at Lindow Moss near Wilmslow in Cheshire, North West England. The remains were found on 1 August 1984 by commercial peat cutters. Lindow Man is not the only bog body to have been found in the moss; Lindow Woman was discovered the year before, and other body parts have also been recovered. The find was described as "one of the most significant archaeological discoveries of the 1980s" and caused a media sensation. It helped invigorate the study of British bog bodies, which had previously been neglected. Dating the body has proven problematic, but it is thought that he was deposited into Lindow Moss, face down, sometime between 2 BC and 119 AD, in either the Iron Age or Romano-British period. At the time of death, Lindow Man was a healthy male in his mid-20s, and may have been of high social status as his body shows little evidence of having done heavy or rough physical labour during his lifetime. There has been debate over the reason for his death; his death was violent and perhaps ritualistic. The recovered body has been preserved by freeze-drying and is on permanent display at the British Museum, although it occasionally travels to other venues such as the Manchester Museum.
=== Minor leagues (1949–51) === Mizell's first team was the Albany Cardinals of the Class D Georgia–Florida League. His first pitch for the team sailed 20 feet over the backstop. Overcoming homesickness, he went on to help Albany win the pennant. He had a 12–3 record and a 1.95 earned run average (ERA) for Albany, recording 175 strikeouts in 141 innings pitched. Promoted to the Class B Winston-Salem Cardinals of the Carolina League in 1950, Mizell got off to a 1–6 start. However, he went on to post a 17–7 record, finishing tied (with Wes Livengood) for fourth in the Carolina League in wins and second (behind Woody Rich) in ERA with a 2.48 mark. He struck out 227 batters in 207 innings, leading Winston-Salem to a championship. In the last game of the season, he hit a home run, the only professional one of his career, which he referred to as a $220 home run because fans passed a hat around and donated that sum in appreciation of his efforts. One night during the season, he sang country music over the public address system at South Side Park and rode around the field on a mule. In 1951, Mizell pitched for the Houston Buffaloes of the Class AA Texas League. The team held a "Vinegar Bend Night," flying in 32 visitors reportedly from the town in Alabama for the evening's game. Because the town was so small, Mizell said that some of the guests "must've come from the suburbs." He had 15 strikeouts in that game, a 3–1 loss to the Shreveport Sports. In another outing, against the Dallas Eagles, he struck out 18 batters, tying the league's single-game record.
===== Oxford Happiness Questionnaire ===== Psychologists Peter Hills and Michael Argyle developed the Oxford Happiness Questionnaire as a broad measure of psychological well-being. The approach was criticized for lacking a theoretical model of happiness and for overlapping too much with related concepts such as self-esteem, sense of purpose, social interest, kindness, sense of humor and aesthetic appreciation.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
Reversed-phase HPLC separates the sample into peaks, and the main peak is expressed as a percentage of total peak area. Mass spectrometry is then used to confirm that the molecular mass matches the expected value.